8-K

U.S.SECURITIES AND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K

CURRENTREPORT

PURSUANTTO SECTION 13 OR 15(d) OF

THESECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 17, 2020

AKERSBIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

201Grove Road

Thorofare,New Jersey USA 08086

(Address of principal executive offices, including zip code)

(856)848-8698

(Registrant’s telephone number, including area code)

NotApplicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Securities registered pursuant to Section 12(b) of the Act:

Item8.01 Other Events.

From April 7, 2020, through April 16, 2020, warrants to purchase an aggregate of 1,043,500 shares of Series C Preferred Stock of Akers Biosciences, Inc. (the “Company”) were exercised at an exercise price of $4.00 per share of Series C Preferred Stock, which were immediately converted into an aggregate of 1,043,500 shares of the Company’s common stock. Following the warrant exercises and the conversion of shares of Series C Preferred Stock issued upon exercise of the warrants into shares of common stock, as of April 17, 2020, we have 4,755,407 shares of common stock issued and outstanding, and outstanding warrants to purchase 946,500 shares of Series C Preferred Stock, which would be convertible into an aggregate of 946,500 shares of common stock at the conversion price in effect as of April 17, 2020.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.